Bleeding Disorders Testing Market By Product (Reagents and Consumables, Instruments) , By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By End User (Hospitals and Clinics, Diagnostic Centers, Others) : Global Opportunity Analysis

Bleeding Disorders Testing Market By Product (Reagents and Consumables, Instruments) , By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By End User (Hospitals and Clinics, Diagnostic Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

The bleeding disorders testing market was valued at $90.9 million in 2023, and is projected to reach $192.0 million by 2033, growing at a CAGR of 7.8% from 2024 to 2033.

Bleeding disorders are a group of medical conditions that impair the body’s ability to control blood clotting or coagulation, a process essential to prevent excessive bleeding after an injury. For diagnosing disorders that cause excessive bleeding or bruising, bleeding disorders testing are used to identify and evaluate conditions that affect the blood’s ability to clot. Early diagnosis through testing is essential for effective treatment and management, as it helps prevent potential complications, including joint damage, internal bleeding, and life-threatening hemorrhages.

The growth of the global bleeding disorders testing market alarming increase in prevalence of bleeding disorders and rise in awareness of early and accurate diagnostic testing. As per a 2022 study by Statista, approximately 208,957 individuals worldwide were suffering from hemophilia A and around 17,626 individuals had other platelet disorders. This emphasizes the urgent need for bleeding disorders testing to reduce the risk of these disorders and improve long-term outcomes. In addition, rise in trend of personalized medicine, which involves tailoring treatment plans as per individual's needs, fosters the market growth. This is attributed to the fact that personalized treatment plans require specific diagnostic testing to identify the precise nature of a bleeding disorder. Furthermore, as healthcare systems in emerging economies improve, access to diagnostic testing for bleeding disorders is increasing, thus expanding the market. Moreover, increase in newborn screening programs to enable early diagnosis and treatment of bleeding disorders acts as a key deterrent factor of the global market. These programs aim to reduce complications from undiagnosed conditions and improve long-term health outcomes. For instance, in 2018, the World Federation of Hemophilia developed a global registry, the WBDR, that allows hemophilia treatment centers to collect clinical data, monitor patient care, and identify gaps in management & treatment. However, high cost associated with genetic and molecular testing for bleeding disorders restrains the market growth. In addition, lack of awareness about bleeding disorders results in underdiagnosis and low demand for testing, which acts as a key deterrent factor of the global market. On the contrary, development of advanced diagnostic tools, including genetic testing and point-of-care diagnostics, has improved the accuracy and speed of bleeding disorder detection, leading to higher adoption rates in healthcare settings. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.

The global bleeding disorders testing industry is segmented into product, indication, end user, and region. On the basis of product, the market is bifurcated into reagents & consumables and instruments. Depending on indication, it is divided into hemophilia A, hemophilia B, Von Willebrand disease, and others. By end user, it is segregated into hospitals & clinics, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product, the reagent & consumables is expected to dominate the market from 2024 to 2033.

Depending on indication, the hemophilia A is anticipated to exhibit the highest growth during the forecast period.

By end user, the hospitals & clinics segment is projected to lead the bleeding disorders testing market in the near future.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global bleeding disorders testing market include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Grifols S.A., Danaher Corporation, Medtronic Plc, and Novo Nordisk A/S. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Key Market Segments

By Product

Reagents and Consumables
Instruments

By Indication

Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By End User

Hospitals and Clinics
Diagnostic Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

Key Market Players

Siemens Healthineers
Abbott Laboratories
Roche Diagnostics
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Grifols S.A.
Danaher Corporation
Medtronic plc
Novo Nordisk A/S